News

A $2.7 million grant from the National Heart, Lung, and Blood Institute, part of the National Institutes of Health (NIH), has been awarded to two stem cell researchers at the University of Houston investigating an alternative cause of chronic lung inflammation in people with cystic fibrosis (CF). The project,…

People from ethnic minority backgrounds were significantly less likely to be eligible for the cystic fibrosis therapy Kaftrio (ivacaftor/tezacaftor/elexacaftor) than white patients, according to a recent U.K. study. Given that the therapy is the most effective CF therapy on the market, “the CF community should urgently address the…

Several potential biomarkers of nontuberculosis mycobacteria (NTM)-associated lung disease were identified in the breath of people with cystic fibrosis (CF) in a recent pilot study. The approach may offer a faster way of reaching an NTM diagnosis, which has historically relied on slow bacterial culture techniques that sometimes delay…

Certain variations in the gene that codes for the inflammatory signaling molecule TGF-beta1 are associated with faster lung function decline and a higher risk of Pseudomonas infections for people with cystic fibrosis (CF), a new study indicates. “Our results demonstrate the relevance of the multifunctional cytokine [signaling molecule]…

A detailed analysis of lung tissue of cystic fibrosis (CF) patients found specific changes to the extracellular matrix (ECM), the three-dimensional network of molecules and proteins outside the cell that supports lung function, a study showed. Drivers of ECM breakdown may act as therapeutic targets or biomarkers to monitor…

There is wide clinical variety in the presentation of individuals who carry one F508del mutation and one 5T;TG12 mutation in the CFTR gene, an Italian study highlights. Its researchers stressed the need to monitor individuals with this genotype, since there are not currently accurate ways to predict who is at highest risk…

ReCode Therapeutics’ investigational aerosolized RNA-based therapies for cystic fibrosis (CF) restored CFTR function, the defective protein in CF, in patient-derived lung cells. Delivered by the company’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform, the therapy showed no signs of toxicity in epithelial cells that line the airways.

LungFit GO, inhaled nitric oxide (NO) that can be self-administered at home, was well tolerated and improved various quality of life measures, according to recent data from a pilot study that evaluated the experimental treatment in adults with or without cystic fibrosis (CF). The ongoing study involves people…

For the first time, bacteriophages — viruses that kill bacteria — eliminated an antibiotic-resistant mycobacterial lung infection in a man with advanced cystic fibrosis (CF) lung disease, a study reported. As a result, the patient was able to undergo a successful lung transplant after one year of bacteriophage treatment.

Lab-edited transfer RNA (tRNA) molecules revived the production of a protein that’s lost or faulty in cystic fibrosis patients’ cells that carry mutations in the protein’s coding gene, a study found. They did this by helping the cell machinery read through the mutations that would cause protein production to…